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IMMUNOCONTRACEPTION AS A TOOL FOR CONTROLLING 
REPRODUCTION IN COYOTES 
LOWELL A MILLER, U. S. Dcpatment of Agriculture, National Wildlife Research Center, 17 16 Heath Parkway, 
Fott Collins. CO 80524 
Abstract: The development of imrnunocontraception as a tool for population management of coyotes (Canis 
la~.ans) and reduction of coyote predation may provide an environmentally safer alternative to pesticides. Because 
they are proteins, ~mmunocontraceptive vaccines do not persist in the environment or bioaccumulate in the food 
chain. The National Wildlife Research Center (NWRC) will examine the effects (immunological, holmonal and 
behavioral) of treating penned coyotes with 2 imrnunocontraceptive vaccines: porcine zona pellucida (PZP) and 
gonadotropin releas~ng hoimone (GnRH). Initial studies will be conducted using traditional subcutaneous 
injections; howeva-, the goal IS to develop an orally-deliverable immunocontraceptive vaccine as an alternative 
tool for coyote populat~on management 
Livestock predation by coyotes is a chronic 
conern of many sheep and goat ranchers. A 1990 
survey estimated that, of the nearly 6 million lambs 
born in the 16 westeln states, 549,000 lambs died 
from all causes (Connolly 1992). Nearly 60% of 
the losses were a I-esult of predators. Coyotes were 
the main culprit, accounting for 70% of the 
predator-caused mot-talltles The econonlic impact 
on producers and consumers 11.1 1990 was approxi- 
mately $1 1 4 million Desp~te intensive historical 
control effol-1s in livestock production areas, and 
despite spoil hunting and trapping for fur, coyotes 
cont~nue to thrivc and expand their range, occu11-ing 
w~dely across North and Central America 
Scientists at the Nat~onal Wildlife Research 
Center and its prcdeccssor laboratories have con- 
ducted research for over 50 years on the problem of 
livestock pl-edation by coyotes, and on developing 
methods to min~mize predation losses Available 
techniques include husband~y practices, shooting, 
trapping, frightening devices, livestock guarding 
dogs and tos~cants (Fall 1990). None of these 
control methods is completely practical or effective 
in all of the diverse situat~ons in which coyote 
predation on l~vestock occurs. Also, as the costs of 
labor-intens~ve skills and appl-oaches continue to 
increase, new techn~ques are needed. Further, 
coyotes are viewed increasingly by the public as a 
desirable w~ldl~fe  speclcs Accordingly, efl'ective 
nonlethal methods are being sought for resolution of 
predation problems 
Immunocontraception has been suggested as 1 
nonlethal technique with application for reducing 
coyote numbers In areas where they are causing 
depredat~on losses, or for managing the predatory 
behavior of tell-~tol-ial pairs (Knowlton 1989). 
However, private industry has had little economic 
incentive to develop new materials for this use 
because of the small quant~t~es of materials that 
would be used in predation control This situation 
with mlmunoconkaception vaccines parallels that for 
toxicants and other coyote predation control prod- 
ucts (Linhai-t et al 1992). 
Basics of immunocontraception 
The neonatal veltebl-ate immune system devel- 
ops a recogn~tion of "self' proteins, carbohydrates, 
and holmones. This self recognition is essential, 
since the production of antibodies against pathogenic 
bacteria and viluses is necessary for survival. 
However, the foimation of antibodies against "self' 
can be an abnolmal destructive process, e.g., dis- 
eases like multiple sclerosis and arthritis. 
The entire immune system is in constant surveil- 
lance to detelmine "self' vs "foreign" proteins. For 
example, in the digestive ti-act, particles and organ- 
isms are examined and either tolerated or attacked 
by antibodies The respiratory and intestinal muco- 
sal surfaces contain various white blood cells (lym- 
phocytes and macrophages) that are responsible for 
generating specific immune responses. In the small 
intestine, groups of lymphoid cells known as Peyer's 
patches (PP) sample bits of food proteins and micro- 
organisms as they pass through to determine if an 
immune response will be directed against the incom- 
ing organism or food particle. 
Anti-fertility vaccines are directed against "self' 
reproductive antigens (holmones or proteins) to 
which the recipient normally is immunologically 
tolerant. These antigens are made "non-self' or 
"foreign" by coupling them to a protein that is 
recognized as fore~gn to the animal. As the animal' 
immune system exanlines the conjugated self-fore~gn 
protein, antibodies are produced to its own repro- 
ductive proterns and holmones This Induced 
immune response agalnst "self' is the key to 
immunocontracept~on The mfer-tility lasts as long as 
there are suflic~ent antrbod~es to intelfere wrth the 
biological activ~ty of the targeted hormone or repro- 
ductive protein, usually 1-2 years. 
Reproductive hormones and proteins involved in 
immunocontraception 
Immunocontraceptive vaccines can control 
reproduction at various stages They can interrupt 
the reproductrve activrty of both sexes by (a) inter- 
ferrng with the biological act~vrty of hornlones, (b) 
block~ng spelni penetration of an ovulated egg, or 
(c) preventing implantat~on and development of a 
fertilized egg 
Gonadotropin releasing holmone (GnRH) 1s 
produced in the bra~n by the hypothalamus and 
controls release of the pituitaly reproductive hor- 
mones follrcle stimulating holmone (FSH) and 
luteinizing hormone (LH). These ho~mones in turn 
control the hormonal hncrions of the gonads (ova- 
ries and testes) Antibodies to the hypothalamic 
hormone will reduce the crrculating level of 
biologically-active GnIUI, thereby reducing the 
release of subsequent reproductive hormones. The 
reduction or absence of these hormones leads to 
atrophy of the gonads, resulting in infertil~ty in both 
sexes. Both avran and mammalian f o ~ m s  of GnRH 
have been Identified. 
The zona pellucida (ZP) is an acellular glyco- 
protein surrounding the egg or oocyte. It is located 
on the outer surface of the egg between the oocyte 
and the granulosa cells. Antibodies to this glyco- 
protein layer result in infertility by 1 or both of these 
actions: (a) blocking sperm from binding to the ZP 
layer, and (b) interfering with oocyte maturat~on. 
For a sperm to fertilize the egg, it must first bind to 
a receptor on the ZP. An enzyme in the sperm 
breaks down the ZP and allows the sperm passage 
Into the ovum. Ant~bodies to the ZP also prevent 
fertilization by interfering with oocyte-granulosa cell 
communication, resulting in the death of the devel- 
oping oocyte (Dunbar and Schwoebel 1988). 
Smce protein in the sperms' head normally bind 
to the ZP receptor on the oocyte, antibodies to these 
sperm prote~ns can be produced, by vaccination in 
the female that are available to bind to sperm In the 
oviduct. This prevents sperm fiom binding to the ZP 
receptor Sperm protein immunocontraception IS 
belng investrgated for contraception of the red fox 
and the rabbit In Australia (Morel1 1993, Tyndale- 
B~scoe 199 1) A ZP protein has not been identified 
in avian species, nor has the cross-reactivity of PZP 
been tested in avian species. 
Chorionic gonadotropin (CG) holmone, which 
is produced by the Implanting embryo in some 
species, induces the corpus luteum to continue 
production of progesterone which is required for the 
maintenance of pregnancy. Ant~bodies to CG reduce 
blood levels of this holmone and thereby prevent 
~mplantation of the fertilized egg. 
The riboflav~n requirement of the developing 
emblyo is sat~sfied by active transport of this water- 
soluble v~tamin across the placenta. This transport 
is provided by a gestatronal-specific carrier protern 
called riboflavin carrier protein (RCP). RCP plays 
a pivotal role in emb~yo development in avian and 
mammalian specles. Antibodies formed agalnst 
RCP interfere w~th  placental transfer of riboflavin, 
thereby preventing development of the early embryo. 
This technology probably would result in the least 
change in social behav~or of the target species of any 
of the proposed vaccines (Natraj et al. 1987, 1988). 
Reproduction can be blocked at many sites in 
the reproductive process; the above examples are the 
sites where most investigative work has been done. 
Behavioral and social changes in target animals 
result~ng from specific vaccines may dictate the 
vaccine of choice in each s~tuation (Jones 1982, 
Griffin 1992). 
Methods of  adrr~inistering vaccincs 
Subcutaneous or intramuscular (I M.) injection 
are the traditional f o ~ m s  of vaccine delivery. In 
order to accomplish I M injections in free-roaming 
an~mals, the vaccine must be del~vered by a dart or 
a "bio-bullet" (Kirkpatrick et al. 1990, Tu~ner  and 
Kirkpatrick 199 1, Gall-ot et al. 1992, Tu~ner  et al. 
199 1, .I 992). Whlle these methods may be effective 
in certain confined locations, they are impractical 
when dealing with mobile wildl~fe populations in 
large open areas . 
Except for the oral polio vacclne introduced by 
Dr. Sabul in the 1950s, oral vaccinat~on has received 
little attention fbr humans bccause it requires larger 
quantities of vacclne and 1s less predictable than 
subcutaneous or I M. routes In marnnials, oral 
immunization takes place in the pha~yngeal inlmune 
follicles (e.g., the tonsils) and in the small intestine. 
Thcre are thousands of immune foll~cles throughout 
tlie small intest~nc, wlth a h~gher concentration in the 
distal portion in most specles Vaccines, being 
protern m nature, arc digested rap~dly In the stomach 
when given orally, hence, ~mniunization must occur 
e~ther in thc pharyngeal arca 01- the vaccine needs a 
protective capsule to sur\ll\re passage through the 
stomach then be released In the small intestine 
(McGhee et al. 1992) 
The safest way to deliver the antlgen orally is to 
protect it until it is taken up by the PP and del~vered 
to macrophages A combination of 2 approaches 
could lead to effective antlgen uptake and potentla- 
tion of mucosal immune response. (a) entel-ic 
coat~ng of the ant~gen result~ng In delive~y vehicles 
that prevent degradation in  the stomach but allow 
absorption in the intestlnc, and (b) des~gning the 
vaccine to have enhanced attraction to the immune 
follicles In the small ~ntestine 
Recent underst:~nding of the n~echanisn~s by 
wh~ch pathogenic \Illuses and bacteria colonize and 
Infect the intestinal tract has provided new insights 
for developing successful and safe attenuated l ~ v e  or 
killed, oral vaccines. For example, a bacteria must 
sul-vlve the stomach's acid and proteolytic enzymes 
to successh~lly infect the small intestine. After 
surviving intact through the stomach, it must have 
adhesive properties which allow it to adhere to and 
colonize the intestinal wall, resulting in an infection. 
Bacteria without adhesive properties will be carried 
out of the gut w ~ t h  the waste material. 
Liposomes are spherical, artificial biological 
membranes made up of phospholipids and choles- 
terol that can be used to protect oral vaccines from 
digestive tract degradation. Since the liposome 
membrane contains lipids, which are stable in the 
gastrointestinal tract, an antigen placed inside during 
liposome synthesis is protected from gastrointestinal 
degradation. Cholesterol in the membrane adds 
stability and makes it attractive to macrophages in 
the PP where the liposome is taken up rap~dly 
because of the membrane's lipophilic nature. This 
character~stic of the membrane causes the liposome 
to simulate a microb~al cell when presented to the 
immune system The liposome acts as an antigen 
micl-ocanicr capable of targeting the antigen directly 
to the PP. 
I-Iowever, before a hposome can be taken up by 
the mas-ophages, it must bind to the mucosal sutface 
of the ~ntestine; othe~wise it will be swept out with 
the waste material. This mucosal adhesive property 
increases the mucosal uptake efficiency, thus requir- 
ing a smaller oral vacclne dose The most com- 
monly used liposome adhesive is a nontoxlc form of 
the bacterial lectin, cholera toxln (CT), a member of 
a family of enterotoxlns produced by several strains 
of enteropathogen~c bacteria (Holmgren et al. 
1992). Lectins have multiple binding sites and can 
bind to receptors on the liposome as well as to 
intestinal receptors. 
Recent advancements in molecular b~ology and 
immunology have provided us with new tools such 
as "live vectors" as delive~y vehicles. The most 
pmminent use ofthls technology In w~ldlife manage- 
ment is the use of the live vacclnla v i ~ u s  to deliver 
rabies vaccine orally to raccoons (Procyon lotor-) 
and foxes (Vu l l~es  vulpes). The attenuated vaccinia 
virus, a member of the pox vlruses, was used as a 
vaccine agalnst smallpox m humans for over 20 
years. Using recombinant genetic engineer~ng, the 
gene responsible for encoding of the rabies vlrus 
glycoprotein was insetted into the vaccinia virus by 
sclent~sts at the Wistar Institute This recombinant 
pox vi~us,  when given orally, was able to vaccinate 
the target animal against rabies. The tonsil lymphoid 
tissue is thought to initiate the immune response in
these target animals (USDA-APHIS 1991).
Live viral vectors potentially can be used to
deliver a contraceptive vaccine. This delivery
system is currently being tested in Australia
(Tyndale-Biscoe 1991).
Potential of immunocontraccption in coyote
management
Immunocontraception as a technology is avail-
able today, but only for use in a laboratory setting
and pen studies. Immunocontraceptive vaccines are
being produced in limited quantities and animals
injected with these vaccines become infertile for 1 -3
years.
The development of a practical, cost-effective
immunocontraceptive vaccine for coyotes is a multi-
year, multi-task project. The first task the NWRC
will undertake will be to determine the immune,
hormonal and behavioral responses to non-species-
specific PZP and GnRH immunocontraceptive
vaccines. Using serum from known lmmuno-
sterilized and fertile coyotes from the above study, a
new mimotope assay will be used to determine
portions of the PZP active in sterilizing the coyote.
This new test may hold promise for finding a PZP
peptide specific to coyotes These species-specific
peptides could then be used to develop a species-
specific ZP vaccine GnRH will continue to be
studied where species specificity is not critical
Some important behavioral questions related to
the effects of contraception on pair formation, pair
bond maintenance, breeding behavior and territorial
defense need to be addressed. The answers may
dictate in pail the choice of vaccines to be developed
for immunocontraception in coyotes
Practical use of immunocontraception for
controlling fi-ee-ranging coyote populations will have
to involve oral delivery of the vaccine The technol-
ogy for developing oral vaccines is in its infancy
However, because of a worldwide need for oral
vaccines against cholera and the HIV vims, rapid
progress is being made in this area. Oral immuniza-
tion using liposome or bacterial vectors will be the
goal of the NWRC Vaccines encapsulated in
liposomes will provide protection from the gastroin-
testinal environment and can induce a 500-fold
greater oral immune response as compared to free
antigens We plan to develop liposomes with a
cholera-toxin-B subunit on their surface to mimic the
adhesive properties of intestinal pathogens and
ensure optimal host immune response.
Finally, prior to field use, U. S Food and Drug
Adrrunistiation approval of the safety and efficacy of
this new vaccine will be needed Extensive labora-
tory, field and product testing will be required before
this or other materials are available for use in man-
agement programs.
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